Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions
暂无分享,去创建一个
Michael T. Frow | U. Banerji | T. Yap | M. O'Brien | R. Punwani | J. D. de Bono | S. Carreira | S. Popat | A. Minchom | M. Puglisi | J. Bhosle | A. Stewart | P. Thavasu | J. Ratoff
[1] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[2] Michael Peyton,et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.
[3] E. Smit,et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. , 2015, Lung cancer.
[4] S. Elledge,et al. RNAi-based functional selection identifies novel cell migration determinants dependent on PI3K and AKT pathways , 2014, Nature Communications.
[5] Zhi-qin Fu,et al. Prognostic value of phospho‐Akt in patients with non‐small cell lung carcinoma: A meta‐analysis , 2014, International journal of cancer.
[6] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[7] Yi-long Wu,et al. Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay , 2014, Chinese journal of cancer.
[8] C. Huang,et al. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts , 2014, British Journal of Cancer.
[9] P. Brauns-Schubert,et al. GSK-3 – at the crossroads of cell death and survival , 2014, Journal of Cell Science.
[10] Haiquan Chen,et al. PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup , 2014, PloS one.
[11] I. Wistuba,et al. The evolving genomic classification of lung cancer , 2013, The Journal of pathology.
[12] G. Mills,et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. , 2014, Cancer research.
[13] Z. Qiu,et al. The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.
[14] G. Giaccone,et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. , 2013, The Lancet. Oncology.
[15] D. Kwiatkowski,et al. Molecular Dissection of AKT Activation in Lung Cancer Cell Lines , 2013, Molecular Cancer Research.
[16] G. Hampton,et al. Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models , 2012, Clinical Cancer Research.
[17] M. Gore,et al. The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer , 2012, Molecular Cancer Therapeutics.
[18] M. Ceccarelli,et al. Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase , 2012, PloS one.
[19] A. Wozniak,et al. Clinical presentation of non-small cell carcinoma of the lung , 2012 .
[20] M. Gore,et al. The Association of PI 3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer , 2012 .
[21] M. Ladanyi,et al. Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling , 2011, Molecular Cancer Therapeutics.
[22] N. Girard,et al. New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.
[23] Dong Sun Kim,et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. , 2010, Lung cancer.
[24] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[25] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[26] Mehmet Toner,et al. Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.
[27] J. Heffner,et al. Diagnosis and management of malignant pleural effusions , 2007, Respirology.
[28] S. Digumarthy,et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.
[29] Jing Fu,et al. [Phophorylated Akt protein expression in non-small cell lung cancer]. , 2007, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[30] H. Sasaki,et al. PIK3CA gene amplification in Japanese non-small cell lung cancer. , 2007, Lung cancer.
[31] H. Sugimura,et al. PIK3CA mutation and amplification in human lung cancer , 2007, Pathology international.
[32] C. Miller,et al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. , 2007, Oncology reports.
[33] S. Steinberg,et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. , 2007, Lung cancer.
[34] M. Meyerson,et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. , 2006, Cancer research.
[35] R. Guo,et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.
[36] H. Wu,et al. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer , 2006, Oncogene.
[37] H. Wu,et al. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. , 2006, Oncogene.
[38] Somasekar Seshagiri,et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.
[39] K. O'Byrne,et al. Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[40] F. Cappuzzo,et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.
[41] J. Jett,et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] R. Ramlau,et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Won Sang Park,et al. Non‐small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[44] D. Rimm,et al. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens , 2002, Cancer.
[45] E. Raymond,et al. Detection of circulating carcinoma cells by telomerase activity , 2001, British Journal of Cancer.
[46] M. Wick,et al. Fixation and Epitope Retrieval in Diagnostic Immunohistochemistry: A Concise Review with Practical Considerations , 2000, Applied immunohistochemistry & molecular morphology : AIMM.